There is inconsistent knowledge on the application of protocols for controlled ovarian stimulation (COS): hormonal as well as functional and genetic biomarkers, individualized approach to COS or the use of LH in COS.

Patients with poor ovarian response represent, even now, one of the most difficult subgroups for ART treatment. A new category of patient based on age and ovarian reserve has been suggested for defining reproductive prognosis and identifying the most appropriate therapeutic strategy.

Andrology and reproductive genetics may benefit many subgroups of infertile patients concerning their reproductive outcome. Moreover, implementing a quality management system in ART clinics and laboratories plays a key role in improving results. All these aspects may contribute to increasing success rates in IVF.

Review the slide kits below for new insight into these topics.

Controlled ovarian stimulation

 
Biomarkers and Pharmacogenomics : What are the new options for COS Standardisation              
                 S. Sunkara, UK
 
The Poor Responders: Aetiology & Management
                  S. Sunkara, UK
 
The role of LH in COS
                J.-N. Hugues, France
 
The Poor Prognosis Patient-The “POSEIDON” Subgroups and management
                 R. Fischer, Germany

Progesterone rise on triggering day-What does it mean?
                J.-N. Hugues, France
 

Improving ART results
  

The Luteal Phase Support-New challenges?
                  R. Fischer, Germany

How Can Andrology help optimizing ART cycles
                 W. Schulze, Germany
 
The role of the reproductive genetics in optimizing ART results
                  K. Held, Germany
 
The Fischer´s Concept for iCOS
                   R. Fischer, Germany